Source: Newsfile Corp • Published: • Sentiment: positive • Ticker: PNGAF
Vancouver, British Columbia–(Newsfile Corp. – July 15, 2026) – The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the “Company” or “BPC”), is pleased to announce that further to its news release dated June 11, 2026, it has closed its previously announced non-brokered private placement of common shares in the capital of the Company (the “Shares”) at a price of $0.50 per Share under the Listed Issuer Financing Exemption (as defined herein) for gross proceeds of $2,000,000 (the “LIFE Offering”) through the issuance of 4,000,000 Shares. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), the LIFE Offering was made to purchasers resident in all provinces of Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 (the “Listed Issuer Financing Exemption”).
This excerpt is quoted from the original release. Read the full announcement on Newsfile Corp.
Brief Summary
The Precision Peptide Company (CSE: BPC) has successfully completed a non-brokered private placement, raising $2,000,000 through the issuance of 4,000,000 common shares at a price of $0.50 each. This initiative is in compliance with relevant regulatory frameworks and highlights strong investor confidence in BPC’s future potential.
- Gross Proceeds: $2,000,000
- Shares Issued: 4,000,000
- Price per Share: $0.50
- Exemption: Listed Issuer Financing Exemption
- Target Market: All provinces in Canada (except Quebec)
Why it matters: This capital infusion will enable The Precision Peptide Company to fuel growth initiatives, strengthen its market position, and enhance shareholder value.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by Newsfile Corp on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.